Signal transducers and activators of transcription (STATs) are key molecular determinants of T-cell fate and effector function. Several inflammatory diseases are characterized by an altered balance of T-cell phenotypes and cytokine secretion. STATs, therefore, represent viable therapeutic targets in numerous pathologies. However, the underlying mechanisms by which the same STAT proteins regulate both the development of different T-cell phenotypes and their plasticity during changes in extracellular conditions remain unclear. In this study, we investigated the STAT-mediated regulation of T-cell phenotype formation and plasticity using mathematical modelling and experimental data for intracellular STAT signalling proteins. The close fit of our model predictions to the experimental data allows us to propose a potential mechanism for T-cell switching. According to this mechanism, T-cell phenotype switching is the result of the relative redistribution of STAT dimer complexes caused by the extracellular cytokine-dependent STAT competition effects. The developed model predicts that the balance between the intracellular STAT species defines the amount of the produced cytokines and thereby T-cell phenotypes. The model predictions are consistent with the experimentally observed interferon-c to interleukin-10 switching that regulates human T helper type 1/ type 1 regulatory T-cell responses. The proposed model is applicable to a number of STAT signalling circuits.
Introduction
Signal transducers and activators of transcription (STATs) regulate cell differentiation, growth, apoptosis and proliferation by transducing signals from the cell membrane to the nucleus. There are seven members of the STAT family in mammalian cells: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. 1, 2 The STAT proteins are activated by binding of a cytokine to its receptor followed by receptor dimerization and phosphorylation of their C-terminal transactivation domain by janus kinases (JAKs). For example, phosphorylation of STAT1 occurs at Tyr701 in response to type II interferons 3 and phosphorylation of STAT3 occurs at Tyr705 in response to interleukin-6 (IL-6) or IL-10. 4, 5 Phosphorylation at Tyr705 leads to dimerization 6 and regulates the activation of STAT3. [7] [8] [9] STATs can form homodimers or heterodimers only with their dimerization partners. 10 STAT dimers translocate to the nucleus, activate gene expression and induce cytokine production. Nuclear phosphatases can dephosphorylate STATs in the nucleus and initiate their return to the cytosol. [11] [12] [13] [14] Alterations in the mechanism of JAK-STAT activation and cytokine production can give rise to various immunerelated pathologies including autoimmune diseases such as rheumatoid arthritis, 15, 16 systemic lupus erythematosus, [17] [18] [19] diabetes 20, 21 and cancer. 22, 23 It was reported in ref. 24 that patients with rheumatoid arthritis lack the so called interferon-c (IFN-c) to IL-10 switching -the transition of the inflammatory IFN-c-only state [T helper type 1 (Th1) cells] into a state characterized by a significant decrease of IFN-c production and a gain of the regulatory IL-10 expression [type 1 regulatory T (Tr1) cells].
Despite extensive experimental research and recent progress in the treatment of the immune-related pathologies, the cause of such diseases is still not clear because of a lack of understanding of the molecular mechanisms at a systems level. Therefore, to further our understanding of the autoimmune states, new systems approaches and mathematical modelling are needed to delineate the molecular mechanisms of T-cell phenotype development and plasticity. 24, 25 Most of the previous mathematical models [26] [27] [28] studied only one signalling pathway at a time, but this limits the power of these models to predict the cellular behaviour in response to the interplay of STAT signalling pathways. Indeed in our previous paper, 29 we also studied phosphorylation of one STAT protein at a time. In this study, we developed a novel systems model to investigate the role of the interplay between multiple STAT proteins in T-cell phenotype plasticity and in IFN-c to IL-10 switching. 24 The developed model integrates separate JAK-STAT signalling pathways into a unified cellular response. The model is based on previously published experimental results [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] and is supported by the new data.
Materials and methods

Mathematical model
In this section, a mathematical description of our model for the STAT3-STAT5 subsystem shown in Fig. 1(b) is provided. We investigated the steady-state solutions of the phosphorylated proteins (STATs) and produced cytokines. The full information about all the reactions and equations governing STAT3-STAT5, STAT3-STAT4 and the combined STAT3-STAT4-STAT5 subsystems can be found in the Supplementary material (Section S2, 'Mathematical model').
Cytokine-receptor interactions
Concentrations of phosphorylated receptor-JAK complexes activated by IL-2, IL-6 and IL-21, respectively, as functions of the corresponding cytokine concentration can be written as follows: 
(here subscripts t and T denote the total amount of protein in non-dimensional and dimensional forms, respectively, small p stands for the phosphorylated state), M 1 , M 2 , M 3 , M 4 , M 5 and M 6 are the non-dimensional Michaelis constants, n 1 , n 2 and n 3 denote the ratio of receptor phosphorylation/dephosphorylation rates. Equations (1) follow from the stationary conditions of the phosphorylation and dephosphorylation of the receptors mentioned previously. The derivation of eqn (1) can be found in the Supplementary material (Section S2.1.1, equations S2-S13).
STAT phosphorylation and dimerization
STAT proteins are phosphorylated by the activated interleukin receptor-JAK complexes IL2Rp:JAK, IL6Rp:JAK and IL21Rp:JAK (Fig. 1b) 
Conservation eqn (4) can be written in a non-dimensional form:
where we introduced the non-dimensional concentrations of the proteins normalized by 
In order to find the steady-state solutions of eqn (3) we need to solve the following system of algebraic equations:
where . System (6) was solved numerically to obtain steady-state concentrations of STAT proteins as a function of IL-2.
SP1 activation
There is an additional, STAT-independent, mechanism for the regulation of IL-10 production. Pathogens can activate the c3-c3b complement system, which leads to the activation of CD46. 46 CD46 can facilitate the production of IL-10 through the STE20/SPS1-related proline/alanine-rich kinase (SPAK) -extracellular signal-regulated kinase (ERK) pathway and SP1 transcription factor in the presence of high concentrations of IL-2. 24 This dependence is described by hypothetical enzymatic reactions shown in the Supplementary material (Section S2.1.3, eqn S33). Hence, it can be written for the concentration of the active SP1 in nondimensional form:
STAT3T , M 16 and M 17 are the Michaelis constants.
Cytokine production
The production of IFN-c and IL-10 is induced by STAT dimer interactions with the genes responsible for production of IFN-c and IL-10. 33 The produced cytokine can be degraded by a factor of degradation Mp (cytokinereceptor binding, diffusion and cleavage by metalloproteases). 47 The concentration of the produced IFN-c in non-dimensional form can be written as follows:
M 18 and M 19 are the Michaelis constants, n 8 is the ratio of IFN-c production to degradation rates. To achieve the steady-state, IFN-c production rate should be less than its maximal degradation rate, which implies n 8 < 1. Both STAT3:STAT3 homodimer and CD46 (through the SPAK-ERK pathway) can activate the same IL-10 gene but they bind different binding regions, as shown in ref. 48 . Interleukin-10 is produced after the binding of either of the transcription factors to the gene, which corresponds to ref. 49 . Hence it can be written for IL-10 concentration:
where, ½i10 ¼ ½IL-10
k11 , M 20 , M 21 and M 22 are the Michaelis constants, n 9 is the ratio of IL-10 production to degradation rates, n 9 < 1. Equations (8) and (9) are used to describe the concentration of produced IFN-c and IL-10 as a function of IL-2.
Equations (7) to (9) are derived in the Supplementary material (Section S2.1.3, Eqns S42, S54 and S55, respectively).
FACS analysis
Blood samples were obtained with ethical and institutional approvals (Wandsworth Research Ethics Committee, REC number 09/H0803/154). T cells were purified from blood samples from healthy volunteers after informed consent. Purified human CD4 + T cells were activated with plateimmobilized antibodies to human CD3 (Okt3) and CD46 (TRA-2-10) in the presence of 50 U/ml recombinant human IL-2 for 36 hr and the percentage of STAT3p-and STAT5p-positive cells was assessed by FACS analysis. Cells were analysed either as a bulk population or after subsorting populations into the three IFN-c AE IL-10-secreting populations generated by CD3/CD46 activation. STAT3p and STAT5p values were normalised against the respective non-phosphorylated STAT protein levels. Standard deviation was calculated for three independently performed experiments using a different donor each time.
Forty-eight-well plates (677180; Greiner Bio-one, Kremsm€ unster, Austria) were coated overnight with (anti-rabbit Violet 450 or AlexaFluor 750, all from BD Biosciences) and analysed on the BD LSRFORTESSA machine (BD Biosciences) using the FLOWJO 9.1 version (FLOWJO, LLC, Ashland, OR, USA) for data analysis.
Results
A new integrative approach for STAT signalling
In this section, a new integrative approach is described that was used to build the systems model. Figure 1 (a) summarizes previously published experimental results [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] and schematically represents the interdependent events in the cytokine/ JAK-STAT signalling pathways (please see Section S1 in Supplementary material for more details). The diagram shows which cytokines activate the known STAT proteins and illustrates the fact that the STAT proteins form homodimers as well as heterodimers only with their dimerization partners. 10 In our model, STAT1 interacts with STAT2, STAT3 and STAT4 only, which is consistent with refs 40-42. Heterodimerization partners for STAT3 are STAT4 and STAT5. STAT4 forms a heterodimer complex with STAT3 and STAT5 whereas the only partner for STAT6 is STAT2. [43] [44] [45] The direct result of the described experimental data integration followed by systems biology analysis is the proposition that cytokine-dependent STAT interactions lead to switching between two tightly regulated systems: the inflammatory IFN-c-only Th1 state into the regulatory Tr1 state characterized by increased IL-10 and decreased IFN-c production levels. 24 Due to the relative complexity of Fig. 1(a) , the scheme was divided into the two subsystems, STAT3-STAT5 and STAT3-STAT4 (Fig. 1b and Fig. 1c respectively) , in such a way that one STAT in each pairing induces the expression of IFN-c while the other induces the expression of IL-10. Here we only focused on the STAT pairings that produce the opposite (inflammatory and regulatory) immune responses.
In contrast to the STAT3 and STAT5 pairing (Fig. 1b) , where IL-2 activates both STAT3 and STAT5, in the STAT3-STAT4 system (Fig. 1c) , IL-2 activates only STAT3 and not STAT4. Due to this role of IL-2 in STAT3, STAT4 and STAT5 activation, we studied the effects of variable IL-2 concentration assuming the continuous presence of the other input cytokines (IL-6, IL-21, IL-12 and IL-35) by fixing their concentrations at constant levels. As a result, the complicated scheme depicted in Fig. 1(a) was divided into the two functionally similar but architecturally different sub-modules shown in Fig. 1(b) and Fig. 1 (c) that can now be described mathematically. The mathematical description can be found in the Materials and methods section and in Supplementary material (Section S2, 'Mathematical model').
The model for coupled STAT3-STAT5 signal transduction
We started our analysis with the STAT3-STAT5 system as illustrated in Fig. 1(b) . To build a model for the STAT3-STAT5 molecular system, we included more biological details into the description of the molecular mechanism such as cytokine-receptor interactions, STAT phosphorylation/dimerization, CD46/SP1 signalling and cytokine production. The description of the governed reactions and equations can be found in the Materials and methods section and in the Supplementary material (Section S2.1).
Using optimization procedures, we obtained a set of parameters to fit our model to the experimental data for IL-2-dependent IFN-c and IL-10 production in Th1/Tr1 switching. The data were taken from ref. 46 and are represented in Fig. 2(a) as circles and crosses for the normalized IFN-c and IL-10 concentrations as a function of IL-2, respectively. The details of parameter optimization, the set of optimized parameters and parameter sensitivity analysis are described in the Supplementary material (Section S3, Figs S1-S6 and Tables S2-S5). Solid lines in Fig. 2(a) illustrate the model predictions for the optimized set of parameters (see Supplementary material, set 'O3' in Table S2 ). Figure 2 (a) visually demonstrates a good fit to the experimental data from ref. 46 , which is quantitatively supported by the small squared error (see Supplementary material, Table S2 ). The figure also shows that with an increase of IL-2, the concentration of IFN-c initially increases reaching a peak and then decreases while the concentration of IL-10 gradually increases, which leads to the switching between Th1 and Tr1 populations. At the same time, there is a population that produces both IFNc and IL-10, the origin of which has not yet been established. 24 Next, we hypothesized that the experimentally established IFN-c to IL-10 switching (Fig. 2a) is due to the STAT competition and caused by the STAT switching. We tested this hypothesis by comparing the model predictions with experimental data for the phosphorylated STAT monomers. Figure 2 (b) shows the model predictions (solid lines) for the STAT redistribution. For low IL-2 concentrations STAT5 is more highly phosphorylated than STAT3, whereas for higher IL-2 concentrations phosphorylated STAT3 prevails over STAT5. To test our model predictions experimentally, we used FACS analysis. Cells were sub-sorted into the three populations, namely IFN-c-only, IFN-c/IL-10 and IL-10-only secreting cells. The levels of phosphorylated STAT3p and STAT5p (normalized to total STAT3 and STAT5, which was not affected by CD46 activation -not shown) were measured in these three cell populations (see Supplementary material, Fig. S7 ). Figure 2(b) shows that the model predictions are consistent with the experimental data for STAT3 and STAT5 phosphorylation levels in the corresponding cell populations. We also tested the hypothesis statistically by variation of the model parameters (see details in Supplementary material, Section S3.2). The parameter sensitivity analysis (see Supplementary material, Fig. S3 ) shows that the switching is still present with higher probability (more than 50%) when the parameters are perturbed within twofold, with modest probability (between 10% and 50%) when the parameters are perturbed within threefold to sixfold and with low probability (< 10%) when the parameters are perturbed within sevenfold and higher. Figure 2 (c) illustrates the model predictions for the STAT3:STAT3 and STAT5:STAT5 dimers, normalized by the total STAT3, on IL-2 concentration. The shapes of the curves for the dimers (Fig. 2c) are similar to the shapes of their monomers (Fig. 2b) due to the high dependence of the dimer concentrations on their monomers. Our model also predicts the bell-shaped dependence of phosphorylated STAT5 on IL-2 as well as STAT5:STAT5 homodimers on IL-2. This bell-shaped dependence suggests that STAT5 is selective to IL-2, or in other words, STAT5 has its maximum activity for a certain range of IL-2, where STAT5 phosphorylation level is high.
Investigation of possible mechanisms of JAK-STAT mediated inflammatory pathologies
We applied the developed model to investigate potential deviations in the immune system caused by changes in the tightly-regulated JAK-STAT signalling pathways. Figure 3(a) illustrates the influence of changes in STAT pathways on IL-10 production. The model predicts that the production of IL-10 can be increased by attenuating the removal of IL-10 by the factors of degradation (increase of our model parameters n 9 and M 20 ) as shown in Fig. 3(a) . The changes in Fig. 3(a) are illustrated for a 15% parameter perturbation of n 9 .
Our model suggests that the production of pro-inflammatory IFN-c can be controlled by various intracellular mechanisms. For example, our model predicts (Fig. 3b) that the magnitude of IFN-c can be reduced by attenuation of the STAT5 pathway signalling (decrease of s5 t ) 50 or by enhancement of the degradation of the produced IFN-c (decrease of M 18 and n 8 ). This may appear to be an expected result as it follows from the structure of the model shown in Fig. 1(b) . However, another prediction of the model is that changes in the STAT3 pathway can also reduce the level of the STAT5-activated production of IFN-c, which is not obvious from Fig. 1(b) . This effect could be achieved by enhancing the formation of the STAT3:STAT5 heterodimer complex (decrease of M 14 ) or alternatively by attenuation of STAT3 dephosphorylation (increase of M 9 ). Figure 3(b) shows the effects of perturbations of these model parameters for a 1.5-fold change of M 9 .
As a result of the parametric alterations, the shape of IFN-c-dependence shifts along the IL-2 axis (Fig. 3c) . According to our model, the alterations of the parameters that cause the IFN-c dependence shown in Fig. 3(c) to shift to higher IL-2 concentrations represent the changes in IL-2 receptor (IL-2R) activation. These changes include a decrease of the total amount of IL-2R (decrease of r2 t ) or enhancement of the dephosphorylation of phosphorylated IL-2R by SHP-1 (decrease of n 1 ). It is notable that although the peak shifts along the IL-2 axis, the magnitude does not change during this transformation. Figure 3(c) shows the effects of n 1 perturbation of one order of its magnitude.
The proposed model suggests new potential strategies for the control of IFN-c selectivity on IL-2 concentration. According to the model predictions, the IFN-c peak shift along the IL-2 axis can also be achieved by alterations in the competing STAT3 signalling pathway, 51 namely by IL-2-mediated STAT3 phosphorylation (parameter M 7 ) as shown in Fig. 3(d) . This effect is a result of indirect interactions due to the redistribution of the STAT complexes as STAT3 does not directly regulate IFN-c production. Our model predicts that due to the effects of competition between STATs, STAT3 indirectly inhibits STAT5, which induces the production of IFN-c.
The developed model also suggests that attenuation of IL-2-induced phosphorylation of STAT5 (increase of M 10 ) reduces IFN-c magnitude and shifts the peak to the range of higher IL-2 concentrations [52] [53] [54] (Fig. 3e) . Our (Table S3; the colour of the arrows in Table S3 corresponds to the colour of the arrows that represent changes shown in Fig. 3 ).
The developed model also predicts how variations in the concentration of IL-6 (Fig. 1b) can affect the switching (Fig. 3f,g ). In our model, the concentration of IL-6 is described by parameter Q 6 as shown in eqn (6) . Figure 3(f) illustrates that a decrease in IL-6 (Q 6 decrease) leads to stronger STAT5 to STAT3 switching, whereas an increase in IL-6 concentration (Q 6 increase) causes changes in both STAT3 and STAT5 phosphorylation levels as a function of IL-2 and thereby the lack of switching. It can be seen from Fig. 3(f) that IL-6 activates STAT3 but at the same time inhibits STAT5 due to the STAT competition, which is consistent with observations in ref. 55 . Due to the role of IL-6 in the STAT competition (Fig. 3f) , IL-6 also affects the STAT-mediated production of IFN-c and IL-10 ( Fig. 3g) . In particular, our model predicts that due to the redistribution between STAT3 and STAT5, increased concentrations of IL-6 lead to the reduced level of pro-inflammatory IFN-c production.
Comparative analysis of STAT3-STAT4 versus STAT3-STAT5 machinery
In this section, we further study the effects of STAT redistribution on the cytokine switching by investigating the STAT3-STAT4 circuit (Fig. 1c) . The cytokines that activate STAT4 include IL-12 and IL-35. In our in silico experiment, we studied the STAT3-STAT4 circuit for variable IL-2 concentrations and constant concentrations of IL-12, IL-35 and IL-6. A detailed description of the model for the STAT3-STAT4 subsystem can be found in the Supplementary material (Section S2.2).
In the absence of any experimental data for STAT4 signalling, we assumed that the parameters in the STAT3-STAT4 subsystem were similar to the parameters in the STAT3-STAT5 subsystem (see Supplementary material, Table S4 ). Figure 4(a-c) shows the model predictions for the STAT3-STAT4 subsystem (Fig. 1c) . The predictions include the competition between STAT3, STAT4 monomers (Fig. 4a) , STAT3:STAT3 and STAT4:STAT4 homodimers (Fig. 4b) as well as IFN-c and IL-10 dependences on IL-2 concentration (Fig. 4c) . Despite the fact that IL-2 does not affect phosphorylation of STAT4 in the STAT3-STAT4 circuit, the switching is nonetheless present in this sub-module.
It should be noted, however, that the model predictions significantly differ between these two circuits for low IL-2 concentrations. The STAT3-STAT5 circuit demonstrates the bell-shaped characteristics with the low IFN-c production for the low amounts of IL-2 ( Fig. 2a) , whereas the STAT3-STAT4 circuit reveals the significant 'background' level of IFN-c (Fig. 4c) . Figure 4 (a) shows that for low IL-2 concentrations there is also a basal phosphorylation level of STAT4. Our model suggests that these 'background' levels of STAT4p (Fig. 4a) and subsequent IFN-c production (Fig. 4c) are due to the STAT4 activation by the maintained initial concentrations of IL-12 and IL-35. 33 After establishing the individual properties of the STAT pathways, we next combined the two STAT3-STAT4 and STAT3-STAT5 circuits (Fig. 5a) . One of the major differences between the full circuit and the smaller submodules is that in the full circuit, STAT3 competes with both STAT4 and STAT5 at the same time (Fig. 5b,e) whereas in the smaller submodules it competes only with either at a time. The detailed description of the model for the (Tables S1 and S2 ). Figure 5 (b-g) illustrates the model predictions for the combined STAT3-STAT4-STAT5 circuit. In the range of low IL-2 concentrations, our model demonstrates two possible scenarios for IFN-c and IL-10 production depending on which of the two phosphorylated STATs, STAT4 or STAT5, prevails. Figure 5(b-d) shows that the combined model predictions qualitatively coincide with the predictions for the STAT3-STAT5 subsystem (Fig. 2) when the amount of phosphorylated STAT4 is significantly reduced in comparison to phosphorylated STAT5. In our model, the reduction of STAT4p is the result of an increase in the total PTP phosphatase concentration. The case shown in Fig. 5(e-g) , where STAT5p is strongly dephosphorylated by increased SHP-2, suggests that the response of the combined model is similar to that of the STAT3-STAT4 circuit considered previously (Fig. 4) . For this system, we observed a significant (compared with phosphorylated STAT5) basal level of STAT4 phosphorylation (Fig. 5e) as well as the 'background' IFN-c production (Fig. 5g) .
Hence, our model demonstrates that the IFN-c to IL-10 switching is still present in the combined model (Fig. 5d,g ). However, in the combined model, in addition to STAT3 competition with STAT4 and STAT5, there is also a competition between STAT4 and STAT5, which leads to the STAT3-STAT4-or STAT3-STAT5-like responses for the low IL-2 concentrations.
Discussion
In this paper, we developed a new integrative model to study complex STAT-STAT interactions in the JAK-STAT pathways (Fig. 1 ). The proposed model was employed to explain the T-cell phenotype plasticity effects using an example of Th1 to Tr1 switching. 24 The model is consistent (Fig. 2a) with the previously published experimental data for IFN-c and IL-10 production. 46 Our model suggests that the IFN-c to IL-10 switching and the associated T-cell plasticity are due to the underlying competition and redistribution of phosphorylated STATs, which is also supported by the new experimental observations ( Fig. 2b and see Supplementary material, Fig. S7 ).
The analysis of our model shows that as a result of this competition, the competing STAT species can indirectly inhibit each other (Fig. 2b) . Moreover, the model suggests that the switching should be the result of the competition between STAT species rather than competition for the source of activating cytokine. This conclusion is supported by the structure of the STAT3-STAT4 scheme (Fig. 2c) , where IL-2 activates only STAT3 in the pairing. Mechanistically, the competition and redistribution between STATs are implemented by the formation of STAT heterodimer complexes.
The necessity of heterodimer complex formation and their functional implications is as yet not clearly understood. 33 According to our model, the role of the STAT heterodimers is to provide a 'buffer', which allows the redistribution of the STAT homodimer complexes. In our model, schematically shown in Fig. 1(a) , we assumed that the STAT homodimers were more effective in mediating gene induction and therefore had a greater contribution to cytokine production compared with the heterodimers, which is consistent with ref. 56 . Therefore, we proposed that the competition between the STAT homodimers might define the type of produced cytokine and, thereby, the T-cell phenotype. Our model suggests that there is a natural balance between STAT homodimers and heterodimers. When there is no signal to switch (which corresponds to a certain concentration of input cytokines), the ratio between the homodimers is balanced. After the T cell receives the signal to switch, this balance is disrupted and then restored again; however, there is now a new ratio between the competing STATs. This newly balanced ratio between the STAT homodimers and heterodimers leads to the new type of produced cytokine and to the Tcell phenotype switching. It should be noted that this is a model suggestion requiring further experimental confirmation.
External and internal factors can alter the model parameters as well as the biomolecular interactions in JAK-STAT signalling pathways. As a result, this can affect the levels of produced cytokines and the T-cell phenotype. We investigated how these alterations can lead to various pathological states without changing the structure of the model (Fig. 3) . Immune-related pathologies caused by Leishmania major or Epstein-Barr virus are associated with an inappropriate balance between pro-inflammatory and anti-inflammatory cytokines. 57, 58 Our model predictions demonstrate possible scenarios of alterations in JAK-STAT pathways that affect IL-10 ( Fig. 3a) and IFN-c production ( Fig. 3b and c) as well as the selective regulation of IFN-c by IL-2 (Fig. 3d,e) . The model predicts that inappropriate regulation of the IL-2R system leads to the dysfunctions of the IFN-c to IL-10 switching (Fig. 3c) , which in turn can mediate autoimmune states such as inflammatory bowel disease. 24, 59 A number of pharmacological and clinical studies have demonstrated aberrant STATs activation in human tumour diseases. It was reported that the inhibition of STAT3 is a promising strategy for anti-cancer treatment. 22, 23, 60 However, there is still a limited understanding of the underlying mechanisms of this inhibition. Our model proposes alternative, interdependent strategies for the regulation of IFN-c and IL-10 production by employing their competing STAT pathways (Fig. 3a-e) . The model predictions suggest that the inhibitor selectivity to specific STAT proteins might enhance the anti-cancer effect.
The [26] [27] [28] only one JAK-STAT pathway was investigated at a time. This fact limits the application of these models to phenotype development and plasticity in response to environmental changes in T cells, where more than one JAK-STAT pathway is involved. 24, 61 The first attempt to introduce the crosstalk between STAT pathways into a systems model was published in ref. 62 . Using an example of STAT1 and STAT3 pathways, the importance of the crosstalk and STAT1: STAT3 heterodimer formation was highlighted in that study. However, the model 62 only considered the dynamics of the STAT system and did not include the production of cytokines, which also rather limits the application of the model to phenotype formation and plasticity involved in a variety of immune diseases.
The fact that our model considers multiple JAK-STAT pathways at a time also provides new insights into the interpretation of some of the conflicting experimental results. 30, 31, 39, 50, 53, [63] [64] [65] [66] For example, it was shown in some studies that the activated STAT5 leads to the production of IFN-c, 50, 53, 63 whereas in another, 64 it was demonstrated that IL-10 production is also enhanced through STAT5 activation. At the same time, the fact that STAT4 activates IFN-c production 30, 31, 39 contradicts other data, 66 showing that STAT4 also induces the production of IL-10. The proposed model offers a potential explanation of this duality in experimental data by introducing selectivity in the JAK-STAT pathways depending on IL-2 concentration (Fig. 2) .
In our work, we focused on one example of proinflammatory IFN-c and regulatory IL-10 production in the Th1/Tr1 phenotype switching via STAT proteins. However, it should be noted that the considered STATs shown in Fig. 1(a) , can also induce the production of cytokines other than IFN-c and IL-10. Therefore, the proposed model can be potentially applied to describe the plasticity effects and the switching not only between Th1 and Tr1, but also other T-cell phenotypes such as Th1/ Th2, 67 regulatory T/Th17 and Th17/Th2 68 phenotype switching.
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